Alyeska Investment Group L.P. grew its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 117.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 73,959 shares of the company's stock after purchasing an additional 39,908 shares during the period. Alyeska Investment Group L.P. owned approximately 0.11% of Mirum Pharmaceuticals worth $8,658,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company's stock valued at $641,764,000 after purchasing an additional 880,505 shares during the last quarter. Jupiter Topco LLC purchased a new stake in Mirum Pharmaceuticals during the 2nd quarter worth approximately $691,672,000. BlackRock Inc. acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter valued at approximately $513,945,000. Vanguard Group Inc. raised its position in shares of Mirum Pharmaceuticals by 2.0% in the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company's stock valued at $205,065,000 after purchasing an additional 50,720 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company's stock valued at $169,354,000 after buying an additional 797,088 shares during the last quarter.
Insiders Place Their Bets
In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 40,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the sale, the senior vice president directly owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Peetz sold 20,000 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the completion of the sale, the chief executive officer directly owned 194,309 shares of the company's stock, valued at approximately $19,221,046.28. This represents a 9.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 103,156 shares of company stock worth $10,888,362. 8.32% of the stock is owned by corporate insiders.
Mirum Pharmaceuticals Trading Up 0.6%
Shares of MIRM stock opened at $98.05 on Tuesday. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00. The firm has a market capitalization of $6.37 billion, a PE ratio of -6.74 and a beta of 0.52. The stock has a fifty day moving average of $110.44 and a two-hundred day moving average of $101.78. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals's revenue for the quarter was up 37.9% on a year-over-year basis. During the same period last year, the business posted ($0.12) earnings per share. As a group, research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current year.
Wall Street Analysts Forecast Growth
MIRM has been the subject of several recent research reports. CLSA set a $146.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Weiss Ratings raised shares of Mirum Pharmaceuticals from a "sell (d-)" rating to a "sell (d)" rating in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $123.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $137.31.
Get Our Latest Stock Report on Mirum Pharmaceuticals
Mirum Pharmaceuticals Profile
(
Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Further Reading
Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Mirum Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.
While Mirum Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
